Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy

ABSTRACT Background and Aim Ropeginterferon alfa‐2b (P1101) is a novel long‐acting mono‐PEGylated recombinant proline interferon (IFN) conjugated to a 40 kDa branched polyethylene glycol (PEG) chain at its N‐terminus, allowing every‐two‐week injection. It received European Medicines Agency and Taiwa...

Full description

Bibliographic Details
Main Authors: Hsien‐Hong Lin, Shih‐Jer Hsu, Sheng‐Nan Lu, Wan‐Long Chuang, Chao‐Wei Hsu, Rong‐Nan Chien, Sien‐Sing Yang, Wei‐Wen Su, Jaw‐Ching Wu, Tzong‐Hsi Lee, Cheng‐Yuan Peng, Kuan‐Chiao Tseng, Albert Qin, Yi‐Wen Huang, Pei‐Jer Chen
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:JGH Open
Subjects:
antiviral
chronic hepatitis C
clinical trial
genotype 1
interferon
ropeginterferon alfa‐2b
Online Access:https://doi.org/10.1002/jgh3.12613

Internet

https://doi.org/10.1002/jgh3.12613

Similar Items